Market Overview

Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients


Gilead Sciences (NASDAQ: GILD) today announced results from two
Phase 2 studies evaluating an all-oral treatment regimen of the
investigational once-daily nucleotide analogue sofosbuvir plus ribavirin
(RBV) for both the prevention and treatment of recurrent chronic
hepatitis C virus (HCV) infection among patients who undergo liver
transplantation. The findings will be presented this week at the 64th
Annual Meeting of the American Association for the Study of Liver
Diseases (The Liver Meeting 2013) in Washington, D.C.

HCV infection is the most common cause of liver transplantation in the
United States and Europe. Recurrence of HCV infection is universal among
patients with active disease at the time of transplantation and up to 50
percent develop cirrhosis

See full press release

Posted-In: News Guidance FDA Global


Related Articles (GILD)

View Comments and Join the Discussion!

Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV

Achillion's ACH-3422 Shows Compelling Preclinical Profile